Baseline characteristics
| Characteristic . | Overall (n = 39) . |
|---|---|
| Median age, y (range) | 58 (22-75) |
| Sex, n (%) | |
| Male | 22 (56%) |
| Female | 17 (44%) |
| Transplanted organ, n (%) | |
| Kidney | 20 (51%) |
| Liver | 13 (33%) |
| Heart | 4 (10%) |
| Lung | 2 (5%) |
| Median time from transplant until PTLD diagnosis, y (range) | 8 (0.5-31) |
| ECOG performance status, n (%) | |
| 0 | 24 (62%) |
| 1 | 13 (33%) |
| 2 | 2 (5%) |
| Ann Arbor stage, n (%) | |
| I | 6 (15%) |
| II | 9 (23%) |
| III | 4 (10%) |
| IV | 20 (51%) |
| International prognostic index, n (%) | |
| 0 | 2 (5%) |
| 1 | 15 (38%) |
| 2 | 12 (31%) |
| 3 | 6 (15%) |
| 4 | 2 (5%) |
| 5 | 2 (5%) |
| Locally assessed histology, n (%) | |
| Diffuse large B-cell lymphoma | 32 (82%) |
| Burkitt lymphoma | 1 (3%) |
| Classical Hodgkin lymphoma-type PTLD | 1 (3%) |
| Polymorphic PTLD | 1 (3%) |
| Polymorphic PTLD, diffuse large B-cell lymphoma, and classical Hodgkin lymphoma-type PTLD | 1 (3%) |
| Plasmacytic hyperplasia, polymorphic PTLD, and other B-cell neoplasms | 1 (3%) |
| Unknown | 2 (5%) |
| Epstein-Barr virus-associated histology, n (%) | |
| Positive | 13 (33%) |
| Negative | 18 (46%) |
| Unknown | 8 (21%) |
| Prior reduction in immunosuppression, n (%) | |
| Yes | 21 (54%) |
| No | 18 (46%) |
| Characteristic . | Overall (n = 39) . |
|---|---|
| Median age, y (range) | 58 (22-75) |
| Sex, n (%) | |
| Male | 22 (56%) |
| Female | 17 (44%) |
| Transplanted organ, n (%) | |
| Kidney | 20 (51%) |
| Liver | 13 (33%) |
| Heart | 4 (10%) |
| Lung | 2 (5%) |
| Median time from transplant until PTLD diagnosis, y (range) | 8 (0.5-31) |
| ECOG performance status, n (%) | |
| 0 | 24 (62%) |
| 1 | 13 (33%) |
| 2 | 2 (5%) |
| Ann Arbor stage, n (%) | |
| I | 6 (15%) |
| II | 9 (23%) |
| III | 4 (10%) |
| IV | 20 (51%) |
| International prognostic index, n (%) | |
| 0 | 2 (5%) |
| 1 | 15 (38%) |
| 2 | 12 (31%) |
| 3 | 6 (15%) |
| 4 | 2 (5%) |
| 5 | 2 (5%) |
| Locally assessed histology, n (%) | |
| Diffuse large B-cell lymphoma | 32 (82%) |
| Burkitt lymphoma | 1 (3%) |
| Classical Hodgkin lymphoma-type PTLD | 1 (3%) |
| Polymorphic PTLD | 1 (3%) |
| Polymorphic PTLD, diffuse large B-cell lymphoma, and classical Hodgkin lymphoma-type PTLD | 1 (3%) |
| Plasmacytic hyperplasia, polymorphic PTLD, and other B-cell neoplasms | 1 (3%) |
| Unknown | 2 (5%) |
| Epstein-Barr virus-associated histology, n (%) | |
| Positive | 13 (33%) |
| Negative | 18 (46%) |
| Unknown | 8 (21%) |
| Prior reduction in immunosuppression, n (%) | |
| Yes | 21 (54%) |
| No | 18 (46%) |